Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort

• DOI: 10.1111/j.1464-410x.2010.09628.x
• Publication Date: 2011-01-18T18:57:25Z
• Authors: Robert S. Svatek; Shahrokh F. Shariat; Giacomo Novara; Eila C. Skinner; Yves Fradet; Patrick J. Bastian; Ashish M. Kamat; Wassim Kassouf; Pierre I. Karakie...; Hans‐Martin Fritsche; Jonathan I. Izawa; Derya Tilki; Vincenzo Ficarra; Bjoern G. Volkmer; Hendrik Isbarn; Colin P. Dinney
• Keywords: Adult; Aged, 80 and over; Male; radical cystectomy; muscle invasive bladder cancer; Discrepancy; Migration; Stage; Survival; Middle Aged; Cystectomy; Prognosis; 3. Good health; Young Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Urinary Bladder Neoplasms; Humans; Female; Neoplasm Recurrence, Local; Epidemiologic Methods; Aged; Neoplasm Staging

Study Type – Prognosis (case series) Level of Evidence 4 What’s known on the subject? and What does the study add? Observations from small retrospective studies have indicated that a considerable number of patients undergoing radical cystectomy for bladder cancer experience a stage migration (either upstaging or downstaging) when comparing clinical and pathological staging. In addition, it is unclear if pathological upstaging is an adverse prognostic feature independent of pathological stage.We report the frequency of upstaging and downstaging using a large, international multicentre cohort of patients undergoing radical cystectomy for bladder cancer without neoadjuvant chemotherapy. Our findings indicate that pathological upstaging is not an independent adverse prognostic feature when considering pathological stage.OBJECTIVE• To compare the clinical and pathologic stage among a large, multi‐institutional series of patients undergoing radical and to determine the effect of stage discrepancy on outcomes.PATIENTS AND METHODS• Data was collected from nine centers and 3,393 patients with urothelial carcinoma of the bladder (UCB) treated with radical cystectomy and pelvic lymphadenectomy without neo‐adjuvant chemotherapy.• A retrospective cohort design was used to assess the percentage of patients experiencing stage discrepancy and the impact of stage discrepancy on time to disease relapse and time to death from UCB.RESULTS• Clinical under staging occurred in 50% of patients and pathologic down staging occurred in 18% of patients.• Up staging to muscle invasive disease occurred in 45.9% (n = 592) of 1,291 patients with clinical ≤T1, including 30.6% of patients with Tis only at transurethral resection.• Of the 3,166 patients with clinically organ confined (OC) tumor stage, 1,357 (42.9%) were up staged to non‐organ confined pathologic tumor stage.• Within each clinical stage stratum, patients who were clinically under staged had a higher probability of disease relapse or death from UCB compared to those who were same staged or down staged on pathologic examination (P < 0.05).CONCLUSIONS• We identified clinical under staging in half of the patients undergoing radical cystectomy for UCB.• Up staging resulted in a higher likelihood of disease progression and eventual death from UCB.• These findings should be considered when utilizing pre‐operative risk‐adapted strategies for selecting candidates for neoadjuvant chemotherapy.